Silihan lan utang jangka dawa perusahaan passagebio.com (PASG)

Passage Bio, Inc. (PASG) develops innovative gene therapy methods for CNS pathologies, leveraging an academic approach and the support of leading geneticists. This chart shows the market price accompanied by the 0.00 indicator. Business stability depends on the outcomes of current trials and prudent capital management. Meanwhile, global tensions and sanctions complicate the logistics of biomaterials and the execution of international tests.

Passage Bio, Inc. (PASG) maintains a monopoly position in pediatric CNS gene therapy, where stringent FDA regulatory control limits the scaling of its client base. The total amount of credit obligations with maturities exceeding one year quantifies financial stability amid limited revenue inflows; therefore, the trend of the issuer's long-term liabilities allows for an assessment of the effectiveness of its deleveraging strategy and the risk of operational downsizing.